YOLFTbeta
Devonian Health Group Inc

Devonian Health Group Inc

GSD · V · Healthcare / Biotechnology

6.30CAD-0.45 (-6.67%)

Price History

Full chart

Market Stats

Previous Close6.75
Open6.30
Day Range6.30 – 6.30
52-Week Range0.19 – 15.00
Volume318
Market Cap22.25M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.25
Dividend Yield0.00%
Beta1.24
50-Day Avg9.01
200-Day Avg10.48

About

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Andre P. Boulet Ph.D.
  • Employees8
  • Headquarters360, rue des Entrepreneurs, Québec, QC, Canada, G5V 4T1, Canada
  • Websitehttps://groupedevonian.com

Leadership

  • Dr. Andre P. Boulet Ph.D.Chair of the Board & CEO · b. 1959
  • Mr. Dennis Turpin CA, CPACFO & Director · b. 1963
  • Mr. Luc D. Gregoire CA, CPAExecutive Vice-President of Strategy · b. 1960

Financials

Income Statement

Currency: CAD2015-07-312016-06-302016-07-312017-07-312018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Total Revenue0-003.20M5.94M2.14M1.47M2.31M2.35M19.31M23.59M
Growth (%)-----+85.56%-63.91%-31.19%+56.32%+1.74%+723.15%+22.19%
Cost of Revenue0-002.95M2.82M2.21M1.72M1.74M1.45M11.83M15.03M
Gross Profit0-00252.76K3.11M-70.12K-240.90K561.01K892.34K7.48M8.56M
Gross Margin----7.90%52.44%-3.27%-16.34%24.34%38.05%38.74%36.28%
Operating Expense1.89M-1.70M1.94M3.09M6.30M4.01M2.02M3.47M5.22M8.09M9.33M
Operating Income-1.89M-172.45K-1.70M-1.94M-2.84M-3.19M-4.08M-2.26M-2.91M-4.32M-613.44K-770.98K
Operating Margin-----88.67%-53.73%-190.32%-153.26%-126.35%-184.37%-3.18%-3.27%
EBITDA----3.34M-2.29M-1.64M-2.57M-1.52M-1.65M-3.72M62.65K-5.10M
EBITDA Margin-----71.42%-27.66%-119.95%-103.28%-71.47%-158.71%0.32%-21.64%
Net Income5.77M-172.45K-1.82M-4.38M-3.19M-2.98M-4.37M-3.35M-3.45M-4.60M-1.83M-6.01M
Net Income Margin-----99.60%-50.18%-204.13%-226.92%-149.59%-196.11%-9.46%-25.49%
R&D116.97K-536.99K426.50K1.12M884.38K1.54M610.25K778.54K1.35M1.29M2.01M
R&D as % of Total Revenue----34.90%14.89%71.71%41.38%33.77%57.74%6.67%8.50%
Interest Expense00000392.86K761.58K793.06K936.97K453.89K369.45K138.36K
Interest Expense % of Total Revenue----0.00%6.62%35.54%53.78%40.65%19.35%1.91%0.59%

Balance Sheet

Currency: CAD2015-07-312016-06-302016-07-312017-07-312018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Total Assets11.73M87.52K10.07M11.56M19.16M17.15M16.70M14.61M21.59M19.18M30.73M15.83M
Total Liabilities6.55M35.36K5.95M3.37M6.42M7.07M7.31M7.08M5.31M4.93M16.87M6.69M
Total Equity5.19M52.16K4.13M8.19M12.74M10.08M9.38M7.52M16.27M14.25M13.86M9.14M
Cash1.01M11.28K528.40K2.20M981.98K244.59K913.02K344.80K2.81M5.06M9.86M6.98M
Net Debt----2.87M4.19M3.75M4.91M1.45M---

Cash Flow

Currency: CAD2015-07-312016-07-312017-07-312018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Operating Cash Flow-1.46M-2.14M-2.43M-2.14M-1.16M-2.03M-1.83M-2.87M-4.36M5.64M-1.25M
Investing Cash Flow-54.97K-12.32K-15.77K130.32K-114.90K-29.47K-14.10K-5.08M---
Financing Cash Flow-614.58K580.14K4.12M790.01K535.43K2.73M1.28M10.41M1.61M-837.39K-1.61M
Capital Expenditure11.77K12.32K071.62K73.67K73.67K73.67K73.67K04.25K17.35K
Free Cash Flow---2.43M-2.21M-1.27M-2.06M-1.85M-2.95M-4.36M5.64M-1.27M
FCF to OCF--100.00%103.34%109.92%101.45%100.77%102.77%100.00%99.92%101.39%

Earnings

Report DateOct 31, 2017Jan 31, 2018Apr 30, 2018Jul 31, 2018Oct 31, 2018Jan 31, 2019Apr 30, 2019Jul 31, 2019Oct 31, 2019Jan 31, 2020Apr 30, 2020Oct 31, 2020Jan 31, 2021Apr 30, 2021Jul 31, 2021Oct 31, 2021Jan 31, 2022Apr 30, 2022Jul 31, 2022Dec 22, 2022Jan 31, 2023Jun 30, 2023Nov 26, 2026
EPS Estimate-----------------------
EPS Actual-0.01-0.01-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-
Surprise-----------------------
Timing-------------------After-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap22.25M
Enterprise Value24.31M
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.43
Price / Book3.57
EPS-2.25
Book Value2.51
Revenue (TTM)3.00M
Gross Profit (TTM)2.03M
EBITDA-5.92M
Profit Margin-204.08%
Operating Margin-1096.23%
Return on Equity-77.33%
Return on Assets-24.50%
Shares Outstanding2.78M
Shares Float2.11M
Beta1.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 22, 20261:60